Innate Pharma S.A. (IPHA)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Add to watchlist

2.5700

+0.1500

(+6.20%)

At close: 04:00PM EDT

Loading interactive chart...

Business Wire
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
MARSEILLE, France, May 07, 2024--Innate Pharma announces conference call and webcast for Q1 business update
Business Wire
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
MARSEILLE, France, April 15, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the first patient was dosed in the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial of SAR443579 / IPH6101 (NCT05086315), evaluating SAR443579 as a monotherapy for the treatment of blood cancers with high unmet needs, including relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia and hig
Business Wire
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
MARSEILLE, France, April 15, 2024--Innate Pharma to hold its Annual General Meeting of shareholders on May 23, 2024